Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Math is a fact
When you average you have highs and lows, you add them and divide them to get an average.
Some scores higher than 4 points better..
Based on precious data and company factual statement( see high dosage in PDD trual) than it is a factual statement that
High Dosage is better than a 4 point improvement.
How anavex is not a $50 stock is a tribute to our broken system in BioPharm investing
That’s not good
I must be reading wrong.. cassava almost 50% better score in 1 year..
see as excellent adjuvant for blarcamesine
Too bad..
But when you are a thief..you steal
You are nicer than me..
They deserve what they get ..
Blarcamesine May stop
A runny nose..
But can’t stop runny mouth disease
I hate auto correct
We have three solid
new Pharma that not only slow
Decline but for some patients
Stop and Reverse decline..
All three have proved as dangerous as placebo ..
What the hell ????
They got these mRNA jabs out
which were never proved safe..
Fining them to pregnant women and babies..
But death demented ex dementia patients
Get NOTHinG! It’s absolutely disgusting
They have no plaque but they have not stopped the disease.. barely slowing it..
It doesn’t work!
The plaque is an outgrowth of the disease
not the disease..
WAit for this…
A total of 257 patients were enrolled; 131 were assigned to receive donanemab and 126 to receive placebo. The baseline iADRS score was 106 in both groups. The change from baseline in the iADRS score at 76 weeks was -6.86 with donanemab and -10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P=0.04). The results for most secondary outcomes showed no substantial difference. At 76 weeks, the reductions in the amyloid plaque level and the global tau load were 85.06 centiloids and 0.01 greater, respectively, with donanemab than with placebo. Amyloid-related cerebral edema or effusions (mostly asymptomatic) occurred with donanemab.
Wow .it’s the same sheet as Biogen without heads blowing up
They really said they didn’t have enough people because so many people got cured?
What the hell is wrong with us?
We are the dumbest generation ever
Link please
The only way I see this stupid posts is when good guys respond to their evil ..
How do you guys start your day like this?
AA never released a negative statement.
Give us one CTAD attendeee who are tacked the data…
You just can’t make up lies about people saying negative things..oh wait..
You can, you just did and it’s still posted..
Guess shorts can say whatever they want..
If they just knew how beautiful Heaven is..
they wouldn’t risk attendance for such underworldly gains
Nath a man of many shares
Just because people who take Blarcamesine:
Fall less
See better
Have fewer heart attacks
Live longer
Remember family better
Are more active
Enjoy life more
Doesn’t mean Blarcamesine works!
What is “is”?
Why it’s whatever they say it is!
Get ‘em falconer!
Add to patent please
My mother in law just took a wicked fall..
Separated shoulder 2 weeks in rehab
Painful night in ER..
Ok .. maybe not..
Then quarterly will be about repeating that we met endpoints, primary and secondary,
And an update on Rett syndrome..
I think .. TGD holding other announcements
To support higher MC once we reach higher MC..over $3 billion
I think peer reviewed will come before the quarterly meeting..
It’s like we are in quiet period until peer review..imo
Anavex will release info with peer review publication..
That’s it..
Then the backlog of data points will be released..one after the other after the other…….
Or???…
So short liars can find a sliver and destroy?
17,000,000 .. got to be close to 20% of outstanding stock is sold without haveing to rever invest..
Then they turn around and destroy instead of create to make money!
Short selling was supposed to be a way
to protect the markets not destroy them..
What a disgusting way to make a living
When they realize it’s tolerate or die
100% will tolerate
Tolerate or obliterate
I choose tolerate
Maybe the king just trying to get back some trading shares or buy back some sold calls cheaper..
Beyond repair?
Beyond ridiculous
Who can afford such tripe?
But Ba..
these decreases may be good..
As they were probably out of whack due to inflammation.. hard to believe they bad if people getting better..
Also what we’re meg side effects please?
Hey Ba..
Maybe..
Blarcamesine May work to slow this drug neg side effects.. while allowing repair..
Blarcamesine isn’t going to work for everyone
Haha
The brutality of lost souls
Sorry just meant to share bottom part..
About calcium disregulation
Adjuvant Match ??? Ya think?
BIOVIEPHARMA.COM
BE PART OF THE
CHANGE
Learn more about a unique opportunity for your loved one to take part in an Alzheimer's disease clinical trial today.
About Our Science
For decades, the direction of Alzheimer’s research focused primarily on the management of amyloid plaques and tau tangles. Some progress has been made, and the road has been difficult; but what if there were new hope, and another path to pursue? Newer research in the past decade has led to over 4,000 research articles that link the problems in memory and judgement in Alzheimer’s to the presence of inflammation and associated insulin resistance in the brain. Among these voices, researchers at the Mayo Clinic showed that over 80% of their Alzheimer’s patients have, or are in the process of developing, Type II diabetes (i.e., insulin resistance). 1
Inflammation initially arises as part of the body’s process to protect and heal itself. When the underlying condition is enduring (as is the case in Alzheimer’s), chronic inflammation may result and create a continuous cycle of disease. Insulin resistance interferes with the body’s ability to process glucose, the essential energy source for cells. This could result in cell damage and death. When this happens in the brain, diminished memory and cognition may result. 2
1 Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004 Feb;53(2):474-81. doi: 10.2337/diabetes.53.2.474. PMID: 14747300.
2 Cunningham C, Hennessy E. Co-morbidity and systemic inflammation as drivers of cognitive decline: new experimental models adopting a broader paradigm in dementia research. Alzheimers Res Ther. 2015 Mar 24;7(1):33. doi: 10.1186/s13195-015-0117-2. PMID: 25802557; PMCID: PMC4369837.
About NE-3107
BioVie’s drug candidate NE-3107 is a new molecule with a unique mechanism of action that is believed to have the potential to interrupt both inflammation and insulin resistance in the brain, which could provide a new approach to treating Alzheimer’s disease. Although Alzheimer’s is a complex condition, BioVie believes that inflammation in the brain plays a central role. Pre-clinical and clinical studies thus far show that NE-3107 has the potential to reduce inflammation throughout the body, including the brain. By reducing inflammation, NE-3107 may allow brain cells to function better and survive longer. Inflammation interferes with the brain’s ability to use energy needed for healthy memory. Because NE-3107 may enhance energy transfer (i.e., improving insulin sensitivity) within the brain, BioVie believes that NE-3107 has the potential to improve memory. In short, the dual effects of reducing inflammation and reducing insulin resistance have the potential together to improve nerve cell function and survival.
Potential Side Effects
In completed clinical studies of NE-3107, when NE-3107 was compared to placebo, the most commonly observed event has been headache (11%) versus placebo (10%). Other possible side effects may include increases in blood glucose levels or cholesterol levels, and decreases in blood calcium levels or blood sodium levels. This is not a full listing of all possible observed events. For a full list of side effects, talk with your physician or reference the informed consent. There also may be unknown or unexpected adverse effects or side effects from the drug.
About The Trial
BioVie is currently conducting a late-stage clinical trial whereby the first fully qualifying 320 patients with mild to moderate Alzheimer’s Disease may participate. Study participants will receive extensive medical testing and treatments. Participants will have about a 50% (1 in 2) chance of receiving NE-3107 and about a 50% (1 in 2) chance of receiving placebo (an inactive capsule that looks like the NE-3107). The study is double-blind meaning that neither you nor the Study Doctor will know who is receiving NE-3107 or placebo. Study participants may be among the first people to have the chance to receive NE-3107, with its unique dual mechanism of action, while contributing to the advancement of medical understanding in treating Alzheimer’s.
Who Qualifies to Participate
• People who are from 60 to 85 years of age at the beginning of their study participation • Show medical evidence of mild to moderate Alzheimer’s Disease, for instance:
- May be getting lost in familiar places
- May become confused while performing previously routine tasks such as bill paying or cooking
- New or worsening challenges with language, writing, math, drawing or copying pictures, or in following multi-step directions
- Decision making may be difficult, or errors in decision making are new or becoming noticeable
- Others may notice words, phrases, or questions are repeated, or the frequency or intensity of repeating has increased
• Generally healthy enough to participate in all study activities and travel
• Have shown an important decline in memory and daily function from a previous higher level of ability • Cause of memory loss is not due to stroke, cardiovascular, or other non-Alzheimer’s causes
• No episodes of violence or aggression
• Not taking insulin
• Has never been diagnosed with breast cancer
Benefits of Participation
• All study treatments and tests at no cost
• Complete physical examinations and comprehensive laboratory evaluations • Detailed evaluations of cognitive function, memory, and recall
• Choice to participate in two types of before and after brain imaging tests:
- Volumetric magnetic resonance imaging (looking at structure and size of brain locations devoted to memory)
- Brain energy testing (looking at how the brain utilizes glucose in a positron emission tomography scan)
• There will be 11 trips to the study doctor over a period of about 7 months
• Study participants and their study partner/caregiver may also receive reimbursement for time spent traveling to the clinic and visits with the doctor
Be a part of a unique opportunity to help advance Alzheimer's research and be a
part of the change for future generations.
Find out how to get involved today.
BIOVIEPHARMA.COM
Dizziness is the drug working!
Obviously these are not investors..
They are short selling thieves
Trying to make money off the suffering of
dementia diseased and weak handed investors
I don’t think 30Mg stablizes ..
helps slow progression..
30mg May be enough for prophylactic effect, but perhaps not enough once disease isn’t in progress.
50mg to stop/halt/ reverse?
Then 30mg to stabilize?
Maybe 30mg seasonally?
Think 30 mg will be seasonal/ prophylactic amount to prevent /slow majority of age related illness